Will BRIUMVI be a serious threat to OCREVUS?

[anonymous]

Wondering if it is a serious threat or is there room for everyone? Price seems lower. I am not in this therapeutic area.

 

[anonymous]

So far they are slow on the uptake. They have a better price, more convenient dosing schedule and no mention of breast cancer issues. Some people are leaving to join them.

 

[anonymous]

No threat, it’s not well known, company isn’t getting their act together, worse safety in Ph 3- and that‘s all they have. Ocrevus is prescribed in >300K patients, safety holds, there is no breast cancer issue- this would have materialized in the 7 years on the market. If NVS wouldn’t do such a half-arsed job, they could be a threat with Kesimpta.